These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24916904)

  • 1. Letter by Dai et al regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".
    Dai Q; Sun W; Liu X
    Stroke; 2014 Jul; 45(7):e132. PubMed ID: 24916904
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to letter regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".
    Whiteley WN; Thompson D; Sandercock P
    Stroke; 2014 Jul; 45(7):e133. PubMed ID: 24916910
    [No Abstract]   [Full Text] [Related]  

  • 3. In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous?
    Kent DM; Hinchey J; Price LL; Levine SR; Selker HP
    Stroke; 2004 May; 35(5):1141-6. PubMed ID: 15087567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population.
    Lokeskrawee T; Muengtaweepongsa S; Patumanond J; Tiamkao S; Thamangraksat T; Phankhian P; Pleumpanupatand P; Sribussara P; Kitjavijit T; Supap A; Rattanaphibool W; Prisiri J
    Curr Neurovasc Res; 2017; 14(2):169-176. PubMed ID: 28356002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA Thrombolysis in Ischemic Stroke trial.
    Zinkstok SM; Beenen LF; Majoie CB; Marquering HA; de Haan RJ; Roos YB
    Stroke; 2014 Oct; 45(10):3080-2. PubMed ID: 25139873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of lysis percentage via thromboelastography for tissue plasminogen activator-induced symptomatic intracranial hemorrhage.
    Gilbert BW; Dingman JS; Huffman JB
    Am J Emerg Med; 2021 May; 43():31-34. PubMed ID: 33493994
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posterior vs. anterior circulation infarction: demography, outcomes, and frequency of hemorrhage after thrombolysis.
    Dorňák T; Král M; Hazlinger M; Herzig R; Veverka T; Buřval S; Šaňák D; Zapletalová J; Antalíková K; Kaňovský P
    Int J Stroke; 2015 Dec; 10(8):1224-8. PubMed ID: 26310390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and short-term outcomes in ischemic stroke in pregnancy or postpartum period.
    Leffert LR; Clancy CR; Bateman BT; Cox M; Schulte PJ; Smith EE; Fonarow GC; Kuklina EV; George MG; Schwamm LH
    Am J Obstet Gynecol; 2016 Jun; 214(6):723.e1-723.e11. PubMed ID: 26709084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reperfusion trials for acute ischaemic stroke.
    Parsons MW; Levi CR
    Lancet; 2012 Aug; 380(9843):706-8. PubMed ID: 22748819
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of intravenous recombinant tissue plasminogen activator administered in the 3- to 4.5-hour window in Korea.
    Park TH; Lee JS; Park SS; Ko Y; Lee SJ; Lee KB; Lee J; Kang K; Park JM; Choi JC; Kim DE; Cho YJ; Kim JT; Kim DH; Cha JK; Han MK; Lee J; Oh MS; Yu KH; Lee BC; Bae HJ; Hong KS
    J Stroke Cerebrovasc Dis; 2014 Aug; 23(7):1805-12. PubMed ID: 24957314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
    Xian Y; Liang L; Smith EE; Schwamm LH; Reeves MJ; Olson DM; Hernandez AF; Fonarow GC; Peterson ED
    JAMA; 2012 Jun; 307(24):2600-8. PubMed ID: 22735429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria.
    Cronin CA; Shah N; Morovati T; Hermann LD; Sheth KN
    Stroke; 2012 Jun; 43(6):1684-6. PubMed ID: 22535272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: a meta-analysis of cohort studies and randomized controlled trials.
    Pan X; Zhu Y; Zheng D; Liu Y; Yu F; Yang J
    Int J Stroke; 2015 Apr; 10(3):317-23. PubMed ID: 25545076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemorrhagic complications after off-label thrombolysis for ischemic stroke.
    Aleu A; Mellado P; Lichy C; Köhrmann M; Schellinger PD
    Stroke; 2007 Feb; 38(2):417-22. PubMed ID: 17185641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke: The Symptomatic Intracranial Hemorrhage Score.
    Lokeskrawee T; Muengtaweepongsa S; Patumanond J; Tiamkao S; Thamangraksat T; Phankhian P; Pleumpanupat P; Sribussara P; Kitjavijit T; Supap A; Rattanaphibool W; Prisiri J
    J Stroke Cerebrovasc Dis; 2017 Nov; 26(11):2622-2629. PubMed ID: 28826584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke Mimics and Acute Stroke Evaluation: Clinical Differentiation and Complications after Intravenous Tissue Plasminogen Activator.
    Nguyen PL; Chang JJ
    J Emerg Med; 2015 Aug; 49(2):244-52. PubMed ID: 25802155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Alberta stroke program early computed tomography score within 3 hours of onset predicts subsequent symptomatic intracranial hemorrhage in patients treated with 0.6 mg/kg Alteplase.
    Hirano T; Sasaki M; Tomura N; Ito Y; Kobayashi S;
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):898-902. PubMed ID: 21737309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
    Bissig D; Manjunath R; Traylor BR; Richman DP; Ng KL
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):e102-e104. PubMed ID: 28416406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.